BioLineRx Announces Pre-clinical Results Demonstrating the Safety of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity

BioLineRx BLRX announced today that BL-7010, an orally available treatment for celiac disease, was found to be safe and well tolerated in pre-clinical studies conducted to date. The new findings were delivered in an oral presentation by Professor Elena Verdú, Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, Ontario, at the Better Life for Coeliacs 2012 Conference, held in Helsinki, Finland from September 6th-9th. In her talk, Prof. Verdú also presented previously disclosed pre-clinical data demonstrating that BL-7010 reduces gluten toxicity, which were published in the in leading medical journal Gastroenterology. In pre-clinical studies BL-7010 was found to be safe, well tolerated and See full press release